Merck Begins Phase 3 Study of Bomedemstat, an Experimental Drug for Specific Essential Thrombocythemia Patients.

Cantargia (Cantargia AB, Nasdaq Stockholm: CANTA) has updated the anticipated schedules for nadunolimab clinical studies.

Centessa Pharmaceuticals Unveils Late-Breaking Poster on Non-Human Primate Data for ORX142, a New Orexin Receptor 2 (OX2R) Agonist.

Find Therapeutics Announces FDA Approval for FTX-101 Phase 1 Clinical Trial in Chronic Optic Neuropathy Treatment.

The European Commission has authorized the use of Astellas’ PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as an initial treatment for advanced urothelial carcinoma.

Yunovia revealed on the 26th that the Korean MFDS has approved the IND application for a Phase 1 MAD study of ID110521156.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Axalbion Therapeutics Begins Phase 2 Trial for Chronic Cough by Administering AX-8, a New TRPM8 Agonist, to the First Patient.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Zai Lab to Share Early Findings from Phase 1 Study of ZL-1218, a Potential Anti-CCR8 Antibody for Advanced Tumor Therapy, at ESMO Congress 2024.

Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available.

The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.